Influence of Cytokine Release Syndrome in Severe COVID-19 Patients Treated With Tocilizumab Over the Quantiferon TB Gold Plus Results.
作者信息
Sánchez-Martínez Francesca, Arenas-Miras Mar, Jové-Caballé Neus, Knobel-Freud Hernando
机构信息
Infectious Diseases Service, Hospital del Mar, Barcelona, Spain.
出版信息
Arch Bronconeumol. 2021 Apr;57:58-59. doi: 10.1016/j.arbres.2021.02.003. Epub 2021 Feb 13.
Abstract
摘要
相似文献
1
Influence of Cytokine Release Syndrome in Severe COVID-19 Patients Treated With Tocilizumab Over the Quantiferon TB Gold Plus Results.托珠单抗治疗的重症 COVID-19 患者中细胞因子释放综合征对结核菌素纯蛋白衍生物加检测结果的影响。
Arch Bronconeumol. 2021 Apr;57:58-59. doi: 10.1016/j.arbres.2021.02.003. Epub 2021 Feb 13.
2
Comparison of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube tests for patients with active and latent tuberculosis: A prospective cohort study.比较活动性和潜伏性结核病患者使用 QuantiFERON-TB Gold Plus 和 QuantiFERON-TB Gold In-Tube 检测的效果：一项前瞻性队列研究。
J Infect Chemother. 2021 Dec;27(12):1694-1699. doi: 10.1016/j.jiac.2021.08.003. Epub 2021 Aug 16.
3
Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.比较结核感染 T 细胞斑点酶联免疫法（QuantiFERON-TB Gold Plus）和结核感染 T 细胞酶联免疫法（QuantiFERON-TB Gold In-Tube）在结核病高危人群和医护人员中的应用。
J Clin Microbiol. 2018 Jun 25;56(7). doi: 10.1128/JCM.00614-18. Print 2018 Jul.
4
QuantiFERON-TB Gold Plus Is a More Sensitive Screening Tool than QuantiFERON-TB Gold In-Tube for Latent Tuberculosis Infection among Older Adults in Long-Term Care Facilities.QuantiFERON-TB Gold Plus 比 QuantiFERON-TB Gold In-Tube 更敏感，可用于长期护理机构中老年人的潜伏性结核病感染筛查。
J Clin Microbiol. 2018 Jul 26;56(8). doi: 10.1128/JCM.00427-18. Print 2018 Aug.
5
Clinical evaluation of QuantiFERON®-TB Gold Plus directly compared with QuantiFERON®-TB Gold In-Tube and T-Spot®.TB for active pulmonary tuberculosis in the elderly.《QuantiFERON®-TB Gold Plus 与 QuantiFERON®-TB Gold In-Tube 和 T-Spot®.TB 直接比较用于老年活动性肺结核的临床评价》。
J Infect Chemother. 2021 Dec;27(12):1716-1722. doi: 10.1016/j.jiac.2021.08.016. Epub 2021 Aug 16.
6
Sensitivity and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB Gold In-Tube and T-SPOT.TB on active tuberculosis in Japan.在日本，与管内QuantiFERON-TB Gold和T-SPOT.TB相比，QuantiFERON-TB Gold Plus对活动性肺结核的敏感性和特异性。
J Infect Chemother. 2018 Mar;24(3):188-192. doi: 10.1016/j.jiac.2017.10.009. Epub 2017 Nov 3.
7
Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome.住院的新冠肺炎重症高炎症综合征患者中QuantiFERON-TB Gold Plus检测结果不确定的临床意义
J Clin Med. 2021 Feb 26;10(5):918. doi: 10.3390/jcm10050918.
8
Frequency and Factors of Indeterminate QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold PLUS Test Results in Rheumatic Diseases.风湿性疾病中结核感染T细胞检测（QuantiFERON-TB Gold In-Tube）和增强版结核感染T细胞检测（QuantiFERON-TB Gold PLUS）结果不确定的频率及因素
J Clin Med. 2021 Sep 24;10(19):4357. doi: 10.3390/jcm10194357.
9
Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT.新一代 QuantiFERON-TB Gold plus 与之前的测试版本 QuantiFERON-TB Gold IT 直接比较，具有同等的敏感性。
Clin Microbiol Infect. 2016 Aug;22(8):701-3. doi: 10.1016/j.cmi.2016.05.006. Epub 2016 May 13.
10
Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis.对有或无结核病受试者的QuantiFERON-Plus和QuantiFERON-金标管法检测进行分析评估。
Tuberculosis (Edinb). 2017 Sep;106:38-43. doi: 10.1016/j.tube.2017.06.002. Epub 2017 Jun 27.
引用本文的文献
1
Prevalence of indeterminate tuberculosis interferon-gamma release assays in COVID-19 patients: Systematic review and meta-analysis.新型冠状病毒肺炎患者中结核菌素γ干扰素释放试验结果不确定的患病率：系统评价与荟萃分析
Health Sci Rep. 2023 Dec 20;6(12):e1695. doi: 10.1002/hsr2.1695. eCollection 2023 Dec.
2
IGRA test for TB in COVID-19: role of corticosteroids.新型冠状病毒肺炎中结核感染的γ-干扰素释放试验：皮质类固醇的作用
Int J Tuberc Lung Dis. 2022 Nov 1;26(11):1088-1091. doi: 10.5588/ijtld.22.0283.
3
Longitudinal Evaluation of the QuantiFERON-TB Gold Plus Assay in Hospitalized COVID-19 Patients with a First Indeterminate Result: Resolution of Inflammation and Restoration of T-Lymphocyte Counts and Interferon-Gamma Production.对初次检测结果不确定的住院COVID-19患者进行QuantiFERON-TB Gold Plus检测的纵向评估：炎症消退、T淋巴细胞计数恢复及γ-干扰素产生情况
Microbiol Spectr. 2022 Oct 26;10(5):e0185822. doi: 10.1128/spectrum.01858-22. Epub 2022 Sep 13.
4
In Patients with Severe COVID-19, the Profound Decrease in the Peripheral Blood T-Cell Subsets Is Correlated with an Increase of QuantiFERON-TB Gold Plus Indeterminate Rates and Reflecting a Reduced Interferon-Gamma Production.在重症新型冠状病毒肺炎患者中，外周血T细胞亚群的显著减少与结核感染T细胞检测（QuantiFERON-TB Gold）阳性不确定率的增加相关，这反映出γ干扰素产生减少。
Life (Basel). 2022 Feb 7;12(2):244. doi: 10.3390/life12020244.
本文引用的文献
1
Coronavirus Activates an Altruistic Stem Cell-Mediated Defense Mechanism that Reactivates Dormant Tuberculosis: Implications in Coronavirus Disease 2019 Pandemic.冠状病毒激活了一种利他的干细胞介导的防御机制，使潜伏性结核病重新激活：对 2019 年冠状病毒病大流行的影响。
Am J Pathol. 2021 Jul;191(7):1255-1268. doi: 10.1016/j.ajpath.2021.03.011. Epub 2021 Apr 19.
2
Coinfection of Tuberculosis Pneumonia and COVID-19 in a Patient Vaccinated with Bacille Calmette-Guérin (BCG): Case Report.一名接种卡介苗（BCG）的患者发生肺结核合并新型冠状病毒肺炎（COVID-19）感染：病例报告
SN Compr Clin Med. 2020;2(11):2419-2422. doi: 10.1007/s42399-020-00601-9. Epub 2020 Oct 17.
3
Tocilizumab for severe COVID-19: a systematic review and meta-analysis.托珠单抗治疗重症 COVID-19：系统评价和荟萃分析。
Int J Antimicrob Agents. 2020 Sep;56(3):106103. doi: 10.1016/j.ijantimicag.2020.106103. Epub 2020 Jul 23.
4
Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?内皮细胞功能障碍：在严重急性呼吸综合征冠状病毒 2 感染（COVID-19）中扮演重要角色？
Eur Respir J. 2020 Jul 30;56(1). doi: 10.1183/13993003.01634-2020. Print 2020 Jul.
5
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
6
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools.理解 SARS-CoV-2 介导的炎症反应：从机制到潜在的治疗工具。
Virol Sin. 2020 Jun;35(3):266-271. doi: 10.1007/s12250-020-00207-4. Epub 2020 Mar 3.
7
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).ESCMID 研究组（ESGICH）对有合并症宿主感染的共识文件：靶向和生物治疗的安全性：传染病学视角（可溶性免疫效应分子[II]：针对白细胞介素、免疫球蛋白和补体因子的药物）。
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S21-S40. doi: 10.1016/j.cmi.2018.02.002. Epub 2018 Feb 12.
8
Executive summary of the guidelines for the use of interferon-γ release assays in the diagnosis of tuberculosis infection.用于结核病感染诊断的γ-干扰素释放试验指南执行摘要。
Enferm Infecc Microbiol Clin. 2016 May;34(5):304-8. doi: 10.1016/j.eimc.2015.11.021. Epub 2016 Feb 28.
9
Gamma interferon release assays for detection of Mycobacterium tuberculosis infection.γ干扰素释放试验检测结核分枝杆菌感染。
Clin Microbiol Rev. 2014 Jan;27(1):3-20. doi: 10.1128/CMR.00034-13.
10
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement.肿瘤坏死因子拮抗剂治疗相关结核的风险：TBNET 共识声明。
Eur Respir J. 2010 Nov;36(5):1185-206. doi: 10.1183/09031936.00028510. Epub 2010 Jun 7.
Zotero 插件